bionaturis

April Newsletter

Here you are Bionaturis’ latest news

 

 

IN THIS ISSUE

Eduard Punset: “Bionaturis is able to deliver hope throughout innovation”
Roche and Oryzon, a historic agreement for Spanish Biotechnology
“Do your best to respect yourself and the others. Keep informed and learn to communicate”

Let’s get to know…

Juan Jose Infante Viñolo, 40 years old, born in La Linea de la Concepcion (Cadiz). PhD in Sciences at Cadiz University.
 

-When you were a child, what did you want to be as an adult?
Well, I wanted to become an adult. And learn a lot on the way.
-What do you like the most about your job?
Learning every day about Biotechnology. And teaching.
-What are your future challenges?
Making progress in my profesional career, developing more the business field. And doing it reaching agreements for the development of Bionaturis’ products.
-Your favourite dish
Bread and Nutella for breakfast. I can’t live without it.
-A place
Seattle. This place has marked a milestone in my life.
-A film
‘La Grande Bellezza’, by Paolo Sorrentino. I will watch it every birthday from now on.
-A historical figure
For being balanced and in this current context, I think that Nelson Mandela taught the way and manners.
-A book
‘The Wind-Up Bird Chronicle’, by Haruki Murakami.
-A song
‘Manhattan’, from the record ‘Omega’, by Enrique Morente. It’s a version of ‘First we take Manhattan’, by Leonard Cohen.
-What do you usually do in your free time?
Reading about Biotechnology. I am such as those freaks.
-A proposal to get rid of the crisis
We must ask ourselves at each moment if what we are doing has sense. And we must ask the same to everybody. We shouldn’t let anything get by one. Or only a few.
-How do you imagine the world in 20 years?
With more tolerant and prudent people. And using more Biotechnology, of course.

 Juan Jose has […]

April 14th, 2014|Blog english|0 Comments|

Eduard Punset: “Bionaturis is able to deliver hope throughout innovation”

Bionaturis has been honored by the visit of the well-known lawyer, economist and science writer Eduard Punset, who has known at firsthand how cutting-edge biological drugs can be obtained using butterfly caterpillars as living bioreactors.

The visit has been driven by the CEO and company founder Victor Infante, as well as by the general manager, Javier Gallastegui. The president of the Consejo Social of Cadiz University, Ana Alonso; the deputy President of the Confederacion de Empresarios, José Andrés Santos; and the president of the Asociacion de la Prensa de Cadiz, Libertad Paloma, as well as other guests, have also participated in the visit. They have gone over Bionaturis’ facilities being introduced to the unique features of the FLYLIFE platform, one of the industrial-scale system of biodrug manufacturing  with a highest yield per square meter on the market and an obvious example of disruptive innovation.

Eduard Punset has pointed out the breakthrough technology used in Bionaturis, as well as the innovation environment  refreshing every corner of the company: “I have realised that Bionaturis is able to deliver hope throughout innovation”, the guest has stated. Ana Alonso, has also claimed that “companies like Bionaturis are a reference in its sector and we should be proud that they were born as a spin-off of the University. They are working for and to the world from the Cadiz province ”.

‘Let’s talk about Cadiz with’

This activity is part of the cycle ‘Let’s talk about Cadiz with’, organised by Cadiz University along with Confederacion de Empresarios and Asociacion de la Prensa of Cadiz . After knowing Bionaturis’ activity, Eduard Punset will take part at 10th April in a free-access panel unveiling his valuable vision about the potentialities of Cadiz society, the current economic […]

April 10th, 2014|Press english|0 Comments|

“Do your best to respect yourself and the others. Keep informed and learn to communicate”

Communication, respect and a never-ending eager to learn are the cornerstones of  the second point of the Decalogue about the executive role written by Juan José Almagro, president of Bionaturis.

Almagro, recently named deputy President of UNICEF Spain, is a lawyer, PhD in Work Sciences, columnist and writer. After a long and successful professional career in the multinational MAPFRE, he has become an icon of the corporate social responsibility and a reference thinker in the sector. He has been the president of the Boards of Directors at Bionaturis since July 2011.

April 3rd, 2014|Blog english|0 Comments|

Biotechnology bets on vaccines

The research on vaccines has found a great partner in biotechnology. Nowadays, 30 out of 80 biological products in latest stages of clinical development are biological vaccines to fight currently unmet diseases. According to BIOTECH MAGAZINE, while in Asia and South America the great concern are diseases such as dengue, in Western countries the infections acquired in hospitals (called nosocomial infections) are becoming an increasing problem.

In this way, Bionaturis is taking part in the public-private consortium Adelis, looking for alternatives to traditional antibiotics to tackle the more and more common phenomena of resistance.

Tuberculosis, AIDS, malaria, and leishmaniasis, among others, are diseases for what biotechnology is actively looking for solutions. Hence, Bionaturis is developing a recombinant vaccine against canine visceral leishmaniasis that has already shown efficacy and safety in mice and beagle dogs.

For further information on biotechnology advances on vaccines, please click here

March 25th, 2014|Blog english|0 Comments|

Bionaturis’ Capital Increase

Bionaturis (BNT) will sell shares to raise money to expand its business in Latin America and Asia as it states at the Full Document of Capital Increase, published at the MAB official website. The biotech company plans to raise as much as 3 million euros from a capital increase in which it will sell new shares at 7.00 €, with a relevant premium to the current stock price. The shares have gained 136 percent this year, giving the company a market value of 52.2 million euros.

Within this post you can find the details of the capital increase operation. The below translation is intended only for information purpose. In case of any discrepancies, the official Spanish version published at the MAB and Bionaturis websites shall prevail:

Pursuant to the authorization granted by the Ordinary Shareholders’ Meeting held on June 26, 2012, pursuant to the provisions stated in Article 297.1b) of the Spanish Corporation Law (hereafter referred to as “LSC”, following the Spanish acronym), the Management Board unanimously agreed, in its session held on March 4, 2014, to increase the Company’s share capital in the terms and conditions discussed below.

 1.      Issue amount and shares to be issued.

It has been agreed to increase the company’s capital to a total amount of 231.651,80 €, by means of the issuance and release of 441.241 shares of a nominal value of 0.05 € each, plus an issue premium of 6.95 €. All shares belong to the same class and series as those currently circulating, and will be represented by book entries. The new shares shall have the same political and economic rights as those of Bionaturis that are currently circulating, as of the date when the capital increase is declared to […]

March Newsletter

Here you are our March Newsletter with Bionaturis’ latest news.

 

IN THIS ISSUE

Bionaturis seeks solutions to antibiotic resistance
Ana de las Heras: “The first year of Targetfish has been very satisfying”
Bionaturis pushes the MAB in its rise of 2014

Let’s get to know…

Rosa María Osuna Aguilar, 37 years old, born in Llodio (Álava). PhD in Sciences at Cadiz University.
 

-When you were a child, what did you want to be as an adult?
The first thing I remember aswering to this question from adults was: “Mum”
-What do you like the most about your job?
The teamwork and learning from my workmates everyday.
-What are your future challenges?
Helping Bionaturis to become a visionary company.
-Your favourite dish
A large grilled steak.
-A place
The beach.
-A film
‘Mamma Mía’.
-A historical figure
Nelson Mandela.
-A book
‘Sophie’s world’, by Jostein Gaarder.
-A song
‘Hoy puede ser un gran día’, by Serrat.
-What do you usually do in your free time?
Playing with my home boys, doing sports, having walks, watching movies…
-A proposal to get rid of the crisis
Removing the privileges for politicians and keeping on people with true commitment and ideas to grow up the economy.
-How do you imagine the world in 20 years?
I would like to think that it will have less inequalities, a global access to health and education.

 Rosa has been working at Bionaturis as Asistant Manager since November 2006.

Bionaturis seeks solutions
to antibiotic resistance

Bionaturis, a biotechnology company listing at the Spanish MAB, participates in the public-private consortium ADELIS, led by Laboratorios Rovi and involving, besides Bionaturis, the companies Biomedal, Vaxdyn, Althia, and research groups from Virgen del Rocio Hospital, University of Granada, University of Sevilla, University of Cadiz and, Genyo[1] as well. The project, which aims to an overall optimization of drug delivery systems, will last two years and will involve an estimated […]

March 11th, 2014|Blog english|Comments Off|

Ana de las Heras: “The first year of Targetfish has been very satisfying”

Ph.D. Ana de las Heras is coordinating the participation of Bionaturis in Targetfish, the European consortium that is seeking solutions to the most common diseases in aquaculture. The balance after this first year is very positive.

-The research on health for aquaculture is one of the business activities in Bionaturis, what are the main milestones and where does the research head for? What are the next challenges?

Our goal is to offer innovative solutions for the prevention and control of diseases in aquaculture. We are focused on working in different and very important diseases for aquaculture, which, besides, will be useful as model for other ones. We expect to obtain soon the first results of testing new orally formulations in target species.

-In this way, Bionaturis is taking part in the European project Targetfish, that has just turned a year. What´s been the balance so far?

The first year has been very satisfying. Targetfish is a large consortium where most of the main European research groups that are working in immunology, fish pathology and aquaculture are taking part. All our effort is driven to obtain tangible solutions to the main diseases that are affecting European aquaculture. The consortium is very well-headed and there is a great commitment to achieve the set outcomes.

-Why is the research of health in aquaculture so important?

The world population is increasing and needs a first-class protein source. Aquaculture is essential to imbalance and satisfy the growing demand of aquatic products. Nowadays, aquaculture contributes nearly 50% of fish supply for human intake, and it is expected that in 2015 aquaculture will overtake the commercial fishing as main sources of fish protein. The increasing global demand of fish and shellfish, along with the limited capacity of […]

March 10th, 2014|Press english|0 Comments|

Bionaturis pushes the MAB in its rise of 2014

Bionaturis, quoting on the Spanish MAB since January 2012, is one of the companies that are contributing to the Spanish Alternative Stock Market to continue getting records in this new year. During the two months and some days sessions of 2014, the MAB has overtaken all the trading volume of 2013 –considered its take off year- with 278.67 million euros.

Bionaturis peaked its maximum ever last 26th February, reaching 11 euros. After the first two months of 2014, the company has also surpassed the whole trading volume of 2013. Nowadays, it’s one of the stock assets with more profitability and liquidity of this specific market made up of small cap enterprises looking to expand.

For this 2014, the company expects an increasing of its annual turnover in more than 400%.

The general trend in the sector, increasing

The biotechnology sector ended 2013 as the most profitable value in the stock market index with 53.96%. The trend keeps growing in the first weeks of the new year.
Opinion leaders say that it is a sector in expansion around the world with strong links in other areas such as agriculture, the environment and energy. In particular, the biotech sector presents technical and scientific conditions adequate to continue capturing investment also in Spain. This trend is having its pair in Spain, where biotech companies that are quoted on the MAB as AB BIOTICS, NEURON, 1NQUEMIA or BIONATURIS have increased their market capitalization value between 30% – 120% in recent months.

For further information, click here

Bionaturis seeks solutions to antibiotic resistance

Bionaturis, a biotechnology company listing at the Spanish MAB, participates in the public-private consortium ADELIS, led by Laboratorios Rovi and involving, besides Bionaturis, the companies Biomedal, Vaxdyn, Althia, and research groups from Virgen del Rocio Hospital, University of Granada, University of Sevilla, University of Cadiz and, Genyo[1] as well. The project, which aims to an overall optimization of drug delivery systems, will last two years and will involve an estimated 2.6 million € global investment. The initiative is funded by the FEDER-INNTERCONECTA program, coordinated by The Centre for Industrial Technological Development (CDTI, in Spanish).

The activities and goals of Bionaturis within the project are framed in the seek for alternative solutions to the use of traditional antibiotics and tackling the alarming growth of antibacterial resistance. The emergence of multi-resistant bacterial strains is a growing problem of great concern for international health authorities. According to World Health Organization (WHO), a phenomena of resistance appears in 20% of patients treated for tuberculosis and are causing the majority of nosocomial infections acquired in hospitals, leading to more than 300,000 deaths annually in Europe and USA.

From animals to people

The problem is also transferred to animal health. New York Times has recently published a study showing that a majority of 30 antibiotics used in animal feed are linked to the increase of the phenomena of resistance in humans. Bionaturis addresses the problem by a pioneering approach proposing a collection of antimicrobial peptides (AMPs), some of them produced by the FLYLIFE system. Along the project, those AMPs will be tested in animal models using cutting-edge drug delivery systems originated from ADELIS. As a final outcome Bionaturis expects to obtain efficacy and safety data of the tested AMPs in mice models.

Juan José […]

February Newsletter

 

 

IN THIS ISSUE

Bionaturis turns two years on the MAB. 3, 2. 1… ready to take off!
“SMEs are the beginning of the future”
Two out of every three fish dishes will come from aquaculture in 2030

Let’s get to know…

Silvia Ayllón López, 35 years old, born in Arcos de la Frontera (Cádiz), Associate Degree in Business and Finance.
 

-When you were a child, what did you want to be as an adult?
As many girls; a dancer, painter, writer… each day I used to change my opinion but certainly it was an art-related profession and eventually here I am, surrounded by figures.
-What do you like the most about your job?
Being part of a team.
-What are your future challenges?
Adapting as soon as possible to all the changes we are living and meeting expectations.
-Your favourite dish
The soup of wild asparagus my mother cooks.
-A place
The beach, in winter or summer, any beach.
-A film
‘Empire of the Sun’, by Steven Spielberg.
-A historical figure
He isn´t a historical figure yet, but I would like to name Judge Jose Castro.
-A book
‘I Gave You My Whole Life’, by Zoe Valdés.
-A song
‘The Site Of My Break’, by Antonio Vega.
-What do you usually do in your free time?
Being with my daughter, family and friends…
-A proposal to get rid of the crisis
Dismissing every politician that has something to do with some case of corruption or embezzlement.
-How do you imagine the world in 20 years?
So much more technological than now and with this technology more integrated in our day-to-day, not only in the work setting.

 Silvia has been working at Bionaturis as an Accountant Technician since March 2007.

Bionaturis turns two years on the MAB: 3, 2, 1,… ready to take off!

It is just two years ago that Bionaturis started quoting on the […]

February 19th, 2014|Blog english|0 Comments|

Uso de cookies

Este sitio web utiliza cookies para que usted tenga la mejor experiencia de usuario. Si continúa navegando está dando su consentimiento para la aceptación de las mencionadas cookies y la aceptación de nuestra política de cookies, pinche el enlace para mayor información.

CERRAR